Legend Biotech ' s CARVYKTI ® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line…

Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Biotechnology | Health